Lilly's oral obesity drug shows 27-pound weight loss in phase 3 trial
Eli Lilly and Company (NYSE: LLY) reported positive results from a phase 3 trial of orforglipron, an investigational oral GLP-1 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)